Epilepsy Society reassures people that contingency plans are in place for medicines post Brexit
Recent media reports have suggested that some epilepsy drugs have been impossible to stockpile in advance of a no-deal Brexit.
This is based on leaked documents seen by The Sunday Times outlining the risks to patients from potential drug shortages.
We would like to reassure all our supporters that we are in regular contact with the Department of Health and Social Care who have told us they do not have a list of epilepsy drugs that they are worried about.
They are working with pharmaceutical companies to ensure that everyone has sufficient stockpiles of medication and that rerouting plans are in place where necessary. If their current analysis of stock reveals any concerns, they will work with individual companies to make sure sufficient supplies are in place in advance of Brexit (scheduled for 31 October).
Clare Pelham, Chief Executive at Epilepsy Society said: "We entreat people with epilepsy not to rely on leaked documents for information about their prescribed medication. The Department for Health and Social Care is making careful contingency plans and is well aware of the needs of people with epilepsy. We will be meeting again with them shortly for further detailed discussions."
Epilepsy Society is in regular communication with pharmaceutical companies about contingency plans for medication in preparation for Brexit. We will be regularly updating information on our website which you can read here.
You can also read advice from our Medical Director Professor Ley Sander about how to cope if there is a shortage of your medication. Professor Sander also explains some of the reasons that can cause medication shortages, regardless of Brexit.